Table 1 Demographics of patients with PCV receiving different treatments.

From: Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy

 

Group 1 (n = 48)

Group 2 (n = 53)

p value

Age, years

68.83 ± 7.42

64.43 ± 9.55

0.01*

Sex

0.29

Male

33

30

 

Female

15

23

 

Baseline BCVA

0.63 ± 0.42

0.57 ± 0.40

0.45

Baseline SFCT

226.41 ± 96.14

259.98 ± 93.01

0.10

Baseline CRT

301.26 ± 96.31

306.72 ± 95.08

0.79

Baseline OCT biomarkers

SRF

37 (77.1%)

36 (67.9%)

0.42

IRF

16 (33.3%)

6 (11.3%)

0.01*

sPED

24 (50.0%)

38 (71.7%)

0.04*

Total number of IVI

3.57 ± 2.14

3.32 ± 1.88

0.55

Total number of PDT

1.53 ± 0.83

  
  1. Values are presented as the mean ± standard deviation or number (percentage).
  2. Group 1 intravitreal injection of ranibizumab + photodynamic therapy, Group 2 intravitreal injection of aflibercept, BCVA best-corrected visual acuity, CRT central retinal thickness, IRF intraretinal fluid, IVI intravitreal injection, OCT optical coherence tomography, PCV polypoidal choroidal vasculopathy, PDT photodynamic therapy, SFCT subfoveal choroidal thickness, sPED serous pigment epithelial detachment, SRF subretinal fluid.
  3. *Indicates chi-squared test; otherwise, t test.
Back to article page